Project Description

Invited Expert Interview
Interview with: Taofeek Kunle Owonikoko
Interview date: May 29, 2020
Disclosures: Consulting or Advisory Role: Novartis, Celgene, Lilly, Sandoz, Abbvie, Eisai, G1 Therapeutics, Takeda. Seattle Genetics, Bristol-Myers Squibb, MedImmune, BerGenBio, Amgen, AstraZeneca, PharmaMar, Boehringer Ingelheim, EMD Serono, Xcovery, Bayer, Heron Pharmaceutical, ARMO BioSciences, Merck, Genentech/Roche; Other Relationship: Roche/Genentech, EMD Serono; Patents, Royalties, Other Intellectual Property: OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3; SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO; Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor); Provisional patent 61/727,519 (Inventor); Genetic predictor of chemotherapy sensitivity; Research Funding: Novartis, Astellas Pharma, Celgene, Bayer, Stem CentRx, Regeneron, AstraZeneca/MedImmune, Abbvie, G1 Therapeutics, Bristol-Myers Squibb, Corvus Pharmaceuticals, United Therapeutics, Amgen, Loxo/Lilly, Fujifilm, Pfizer, Aeglea Biotherapeutics, Incyte, Merck
Affiliations: Professor, Hematology and Medical Oncology, Winship Cancer Institute of Emory University
Subtitles/Captions:

Disclaimer: Springer Healthcare selected the experts for interview. The expert interviews appearing herein were not prepared or reviewed by ASCO and have not been subject to a peer review process. The ideas and opinions expressed herein do not necessarily reflect those of ASCO. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions. Full disclaimer.

© 2020 American Society of Clinical Oncology (ASCO®). All Rights Reserved.

Subtitles:
Loading...
Invited Expert Interview
Interview with: Taofeek Kunle Owonikoko
Interview date: May 29, 2020
Disclosures: Consulting or Advisory Role: Novartis, Celgene, Lilly, Sandoz, Abbvie, Eisai, G1 Therapeutics, Takeda. Seattle Genetics, Bristol-Myers Squibb, MedImmune, BerGenBio, Amgen, AstraZeneca, PharmaMar, Boehringer Ingelheim, EMD Serono, Xcovery, Bayer, Heron Pharmaceutical, ARMO BioSciences, Merck, Genentech/Roche; Other Relationship: Roche/Genentech, EMD Serono; Patents, Royalties, Other Intellectual Property: OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3; SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO; Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor); Provisional patent 61/727,519 (Inventor); Genetic predictor of chemotherapy sensitivity; Research Funding: Novartis, Astellas Pharma, Celgene, Bayer, Stem CentRx, Regeneron, AstraZeneca/MedImmune, Abbvie, G1 Therapeutics, Bristol-Myers Squibb, Corvus Pharmaceuticals, United Therapeutics, Amgen, Loxo/Lilly, Fujifilm, Pfizer, Aeglea Biotherapeutics, Incyte, Merck
Affiliations: Professor, Hematology and Medical Oncology, Winship Cancer Institute of Emory University
Subtitles/Captions:

Disclaimer: Springer Healthcare selected the experts for interview. The expert interviews appearing herein were not prepared or reviewed by ASCO and have not been subject to a peer review process. The ideas and opinions expressed herein do not necessarily reflect those of ASCO. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions. Full disclaimer.

© 2020 American Society of Clinical Oncology (ASCO®). All Rights Reserved.